The instant application provides methods of diagnosing and treating a subject having IBS. In certain embodiments, the methods also include diagnosing subjects who will respond to IBS treatment with rifaximin. The methods include determining the identity and prevalence of the bacterial community in the gastrointestinal (Gl) tract. In certain embodiments, the microbiome comprises the Gl tract microbiome. In certain embodiments, the microbiome comprises the Gl tract bacterial population. In certain embodiments, the microbiome comprises stool bacterial. The methods include analysis of the identity of the bacterial community in the gastrointestinal (Gl) microbiome to produce a profile of diversity of the bacterial communities.
申请公布号
WO2015171493(A1)
申请公布日期
2015.11.12
申请号
WO2015US29040
申请日期
2015.05.04
申请人
SALIX PHARMACEUTICALS, INC.;GOLDEN, PAM;FODOR, ANTHONY;BORTEY, ENOCH;FORBES, WILLIAM
发明人
GOLDEN, PAM;FODOR, ANTHONY;BORTEY, ENOCH;FORBES, WILLIAM